1
|
Ayala-León M, Aceves-Velázquez E, Barrera-Oranday EA, Cano-Zárate R, Escobedo-Mercado D, Gaxiola-Macías MB, Ilarraza-Lomelí H, Ixcamparij-Rosales CH, Lara-Vargas JA, Meave-González A, Papaqui-Quitl N, Torres-Araujo LV, Tzompantzi-Flores R, Zebadúa-Torres R, Alcocer-Gamba MA. [Consensus document of the Mexican Society of Cardiology for post-COVID-19 cardiovascular clinical follow-up]. Arch Cardiol Mex 2022; 93:115-133. [PMID: 35377577 DOI: 10.24875/acm.21000287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Accepted: 12/20/2021] [Indexed: 11/17/2022] Open
Abstract
Background The cardiovascular sequelae by the SARS-COV-2 infection is prevalent in a significant portion of the recovered patients from the acute presentation of the SARS-COV-2. Actually, the clinic cardiac control of the post-acute COVID syndrome has been working out without a well-established protocol, making the appropriate diagnosis of the cardiac diseases produced by the different damage mechanisms from COVID-19. Objectives Standardize cardiovascular care and the follow up of COVID-19 survivors in the function on disease severity and identify patients who develop SPC-19A for timely care. Materials and methods Through an extensive bibliographic review, this article has the purpose of provide the necessary information to make possible the early diagnosis and following of the cardiac complications that has been recorded trough the months after the acute disease from COVID-19.
Collapse
Affiliation(s)
- Miguel Ayala-León
- Jefatura de la Unidad de Cuidados Intensivos Cardiovasculares, Hospital Beneficencia Española de Puebla, Puebla, México
- Departamento de Cardiología, Facultad de medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México
| | - Eduardo Aceves-Velázquez
- Servicio de Terapia Intensiva Cardiovascular y Ecocardiografía, Instituto Cardiovascular de Mínima Invasión, Guadalajara, Jalisco, México
| | - Ernesto A Barrera-Oranday
- Servicio de Hemodinamia, Unidad Médica de Alta Especialidad 34, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México
| | - Roberto Cano-Zárate
- Unidad de Resonancia Magnética Cardiaca, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Daniel Escobedo-Mercado
- Servicio de Ecocardiografía de Adultos, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México
| | | | - Hermes Ilarraza-Lomelí
- Jefatura de servicio de Rehabilitación cardiaca, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Carlos H Ixcamparij-Rosales
- Jefatura de Alta Especialidad en Ecocardiografía de Adultos, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México
| | - Jorge A Lara-Vargas
- Jefatura de Servicio de Rehabilitación Cardiaca, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México
- Presidencia, Sociedad Mexicana de Cuidado del Corazón, Ciudad de México, México
| | - Aloha Meave-González
- Jefatura de Servicio de Resonancia Magnética Cardiaca, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
- Imagen Cardiaca, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México
| | - Nila Papaqui-Quitl
- Departamento de Cardiología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, México
| | - Laura V Torres-Araujo
- Servicio de Tomografía Computarizada y Resonancia Magnética Cardiaca, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Rosa Tzompantzi-Flores
- Unidad de Cuidados Intensivos Cardiovasculares, Hospital Beneficencia Española de Puebla, Puebla, México
| | - Rodrigo Zebadúa-Torres
- Servicio de Cardioneumología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Marco A Alcocer-Gamba
- Presidencia, Sociedad Mexicana de Cardiología, Ciudad de México, México
- Departamento de Cardiología, Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, México
| |
Collapse
|
2
|
Aceves-Velázquez E, Vieyra-Herrera G, Rodríguez-Chávez L, Herrera-Alarcón V. [Evaluation of the antithrombotic strategy in low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis]. Arch Cardiol Mex 2017; 88:339-346. [PMID: 28720315 DOI: 10.1016/j.acmx.2017.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Revised: 06/13/2017] [Accepted: 06/19/2017] [Indexed: 10/19/2022] Open
Abstract
According to current guidelines, in patients without additional risk factors who have undergone aortic valve replacement with a bioprosthesis, anticoagulation in the first 3 months after surgery is still a matter of debate. According to current evidence, aspirin in low doses is a reasonable alternative to vitamin K antagonists (VKA). A comparison is made between the incidence of thrombotic and haemorrhagic complications in patients with low thrombotic risk who underwent aortic valve replacement with a bioprosthesis in the National Institute of Cardiology of Ignacio Chávez of Mexico. The hypothesis: aspirin as monotherapy has a beneficial effect compared to VKA. The studied patients were the low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis in the National Institute of Cardiology of Ignacio Chávez of Mexico from 2011 to 2015. The groups studied were: aspirin only, VKA only, and the combination of VKA plus aspirin. The patients were retrospectively followed-up for 12 months, and the thrombotic and haemorrhagic complications were documented. Of the 231 patients included in the study, only one patient in the VKA only group presented with a haemorrhagic complication. No thrombotic complications were observed. In the present study no thrombotic complications were observed in patients who did not receive anticoagulation in the first 3 months after an aortic valve replacement with a bioprosthesis after a follow up period of 12 months. This suggests that the use of aspirin only is safe during this period.
Collapse
Affiliation(s)
| | - Gerardo Vieyra-Herrera
- Departamento de Consulta Externa, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Laura Rodríguez-Chávez
- Departamento de Consulta Externa, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| | - Valentín Herrera-Alarcón
- Departamento de Cirugía, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
| |
Collapse
|